Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2024 May 10;8(6):e0421.
doi: 10.1097/HC9.0000000000000421. eCollection 2024 Jun 1.

Reply to: Serological response after COVID-19 vaccination, cirrhosis, and postliver transplant

Maria Pilar Ballester  1   2 , Eva Uson  3 , Rajiv Jalan  3   4 , Gautam Mehta  4
Affiliations
Comment

Reply to: Serological response after COVID-19 vaccination, cirrhosis, and postliver transplant

Maria Pilar Ballester et al. Hepatol Commun. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Gautam Mehta owns stock in Hepyx Ltd. Rajiv Jalan is the inventor of OPA, which has been patented by UCL and licensed to Mallinckrodt Pharma. He is also the founder of Yaqrit Discovery, a spin-out company from University College London, Hepyx Limited, and Cyberliver. He had research collaborations with Yaqrit Discovery. The remaining authors have no conflicts to report.

Comment on

  • Serological response and breakthrough infection after COVID-19 vaccination in patients with cirrhosis and post-liver transplant.
    Mehta G, Riva A, Ballester MP, Uson E, Pujadas M, Carvalho-Gomes Â, Sahuco I, Bono A, D'Amico F, Viganò R, Diago E, Lanseros BT, Inglese E, Vazquez DM, Sharma R, Tsou HLP, Harris N, Broekhoven A, Kikkert M, Morales SPT, Myeni SK, Riveiro-Barciela M, Palom A, Zeni N, Brocca A, Cussigh A, Cmet S, Escudero-García D, Stocco M, Natola LA, Ieluzzi D, Paon V, Sangiovanni A, Farina E, di Benedetto C, Sánchez-Torrijos Y, Lucena-Varela A, Román E, Sánchez E, Sánchez-Aldehuelo R, López-Cardona J, Canas-Perez I, Eastgate C, Jeyanesan D, Morocho AE, Di Cola S, Lapenna L, Zaccherini G, Bongiovanni D, Zanaga P, Sayaf K, Hossain S, Crespo J, Robles-Díaz M, Madejón A, Degroote H, Fernández J, Korenjak M, Verhelst X, García-Samaniego J, Andrade RJ, Iruzubieta P, Wright G, Caraceni P, Merli M, Patel VC, Gander A, Albillos A, Soriano G, Donato MF, Sacerdoti D, Toniutto P, Buti M, Duvoux C, Grossi PA, Berg T, Polak WG, Puoti M, Bosch-Comas A, Belli L, Burra P, Russo FP, Coenraad M, Calleja JL, Perricone G, Berenguer M, Claria J, Moreau R, Arroyo V, Angeli P, Sánchez C, Ampuero J, Piano S, Chokshi S, Jalan R; COBALT Consortium. Mehta G, et al. Hepatol Commun. 2023 Oct 18;7(11):e0273. doi: 10.1097/HC9.0000000000000273. eCollection 2023 Nov 1. Hepatol Commun. 2023. PMID: 37870985 Free PMC article.

References

    1. Daungsupawong H, Wiwanitkit V. Serological response after COVID-19 vaccination, cirrhosis and post-liver transplant: Correspondence. Hepatol Commun. 2023. - PMC - PubMed
    1. Mehta G, Riva A, Ballester MP, Uson E, Pujadas M, Carvalho-Gomes Â, et al. . COBALT Consortium. Serological response and breakthrough infection after COVID-19 vaccination in patients with cirrhosis and post-liver transplant. Hepatol Commun. 2023;7:e0273. - PMC - PubMed